The 3rd and final webinar in the current LAB150-TIAP series will be held on Tuesday, March 23. Please see the link above to register. There are limited number of openings, so please register soon. Feel free to circulate to senior scientists in your networks.
Are you interested in increasing your chances of early success by best practices with TPP, lead indications, manufacturing strategy, IND enabling studies and stratifying populations? In this webinar, we turn our attention to clinical trials. It is essential that one contemplates trial design and endpoints from the earliest stages of drug development. Our panel will discuss the key considerations along the path from early compound optimization to the initiation of your Phase I study. They will look at crucial areas such as:
Defining your final target product profile (TPP)
Selecting the right therapeutic indication(s)
Scale-up and manufacturing strategy
IND-enabling studies – when, who and how
Patient stratification, biomarkers, and endpoints
Join us to learn more about how you best can prepare for a successful clinical trial.
Dr. Ann MacLaren
Ann MacLaren has over 20 years of experience in oncology research, including 14 years in the biotechnology industry with expertise in pharmacology and translation development strategies. Throughout her career, Ann has focused on evaluating novel therapeutics for oncology with a specific focus on guiding and implementing precision medicine strategies for preclinical and clinical development programs. Ann joined Triphase Accelerator in 2014 and is currently Executive Director of Translational Development. She has held positions as Director of Biology at Convoy Therapeutics (2013-2015), Principal scientist at Pfizer (CovX Biotherapeutics Unit, 2011-2013) and Senior Scientist at Biogen Idec Inc (2007-2011). She has led drug discovery programs and developed biomarker strategies for early and late stage clinical programs. Her therapeutic modality experience includes peptides, antibodies, bispecific antibodies, antibody peptide conjugates and antibody drug conjugates. She obtained her Ph.D. in Molecular Biology from the University of Edinburgh (United Kingdom) followed by post-doctoral training at the Beatson Institute for Cancer Research (United Kingdom) and The Scripps Research Institute (San Diego, CA).
Michael has over 20 years of experience in the life science industry, fund management, corporate finance and therapeutic development. Michael has been CEO of Zucara Therapeutics since 2016 and has advanced the company from initial seed funding and proof of concept to securing a US$21M Series A financing moving its lead therapeutic, ZT-01, into Phase 1 clinical trials. Michael was previously an Entrepreneur-in-Residence at TIAP (Toronto Innovation Acceleration Partners) providing management support to its portfolio companies. Michael has also managed an industry/academia focused funding program with Genome Canada and spent nearly a decade with Rosetta Capital, an international venture capital firm. Michael has an MSc in molecular biology from the University of Toronto (Canada) and an MBA from Imperial College Business School (UK). He has also completed the Canadian Securities Course.
Dr. Meenu Chhabra
Meenu Chhabra is an accomplished senior biopharma executive with over 20 years of experience in the global biopharmaceutical industry spanning both private and public large pharma and small biotech companies. She has been a biotech CEO for the last 14 years with her most recent role being at Proteostasis Therapeutics (NASDAQ:PTI) where she completed an IPO and raised approximately $300M USD to fund a proprietary triple combination therapy for the treatment of cystic fibrosis (CF) and launched the first ever personalized medicine registrational study for CF. Meenu is recognized for strategic leadership and strong management skills based on core values of transparency, urgency and focus. She has built a successful track record of driving strategic transactions, meeting and accelerating value-generating milestones, shaping drug pipelines and assets based on developing high-performing organizations. She is a dynamic and influential communicator who is able to execute key initiatives while effectively managing expectations of internal and external stakeholders, including public and private investors, board directors, regulators, scientific advisory board members and technical staff.